Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: August 2012

8 - Evidence-based pharmacotherapy of obsessive–compulsive disorder

Summary

Neuropsychological, neuroimaging, and genetic studies have demonstrated the biological underpinnings of attention deficits hyperactivity disorder (ADHD). These studies have correlated deficits in executive functioning, response inhibition and planning with specific regions of the brain. The multimodal treatment study (MTA) study randomized participants to intensive behavioral therapy, pharmacotherapy with systematically delivered methylphenidate, a combination of the two, or standard community care. The American Academy of Child & Adolescent Psychiatry (AACAP) Practice Parameters for ADHD published in 2007 combine short- and long-term empirical evidence with expert opinion from pediatric mental health researchers and clinicians. A meta-analysis of atomoxetine and stimulant studies revealed a robust effect size for atomoxetine and the stimulants, both of which are currently approved by the food and drug administration (FDA) for the treatment of ADHD. In the interim, appropriate diagnosis, informed prescribing, clinical monitoring, and collaborative treatment planning can all help to optimize outcomes in ADHD management.

References

Aboujaoude E, Barry JJ, Gamel N (2009). Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Journal of Clinical Psychopharmacology 29, 51–55.
Abramowitz JS (1997). Effectiveness of psychological and pharmacological treatments for obsessive compulsive disorder: a quantitative review. Journal of Consulting and Clinical Psychology 65, 44–52.
Ackerman DL, Greenland S (2002). Multivariate meta-analysis of controlled drug studies for obsessive compulsive disorder. Journal of Clinical Psychopharmacology 22, 309–317.
Aizenberg D, Naor S, Zemishlany Z, Weizman A (1999). The serotonin antagonist mianserin for treatment of serotonin-reuptake inhibitor-induced sexual dysfunction: an open-label study. Clinical Neuropharmacology 22, 347–350.
Albert U, Aguglia E, Maina G, Bogetto F (2002). Venlafaxine versus clomipramine in the treatment of obsessive compulsive disorder: a preliminary, single-blind 12-week controlled study. Journal of Clinical Psychiatry 63, 1004–1009.
Ananth J, Pecknold JC, Van Den Steen N, Engelsmann F (1981). Double-blind comparative study of clomipramine and amitriptyline in obsessional neurosis. Progress in Neuro-Psychopharmacology 5, 257–262.
Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006). Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Archives of General Psychiatry 63, 769–776.
Baldwin SD, Anderson IM, Nutt DJ et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 19, 567–596.
Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH (1997). Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. American Journal of Psychiatry 154, 1293–1295.
Beasley CM, Potvin JH, Masica DN et al. (1992). Fluoxetine: no association with suicidality in obsessive-compulsive disorder. Journal of Affective Disorders 24, 1–10.
Bejerot S, Bodlund O (1998). Response to high doses of citalopram in treatment-resistant obsessive compulsive disorder. Acta Psychopharmacologica Scandinavia 98, 423–424.
Bergeron R, Ravindran AV, Chaput Y et al. (2001). Sertraline and fluoxetine treatment of obsessive compulsive disorder: results of a double-blind, 6-month treatment study. Journal of Clinical Psychopharmacology 22, 148–154.
Berlin HA, Koran LM, Jenike MA et al. (2010). Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry. Aug 10. [Epub ahead of print]
Bisserbe JC, Lane RM, Flament MF (1997). A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. European Psychiatry 12, 82–93.
Blier P, Bergeron R (1996). Sequential administration of augmentation strategies in treatment resistant obsessive compulsive disorder: preliminary findings. International Clinical Psychopharmacology 11, 37–44.
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C (2010). Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 15(8), 850–855. Epub 2009 May 26.
Bloch MH, Craiglow BG, Landeros-Weisenberger A et al. (2009). Predictors of early adult outcomes in pediatric-onset obsessive-compulsive disorder. Pediatrics 124(4), 1085–1093. Epub 2009 Sep 28.
Bobes J, González MP, Bascarán MT et al. (2001). Quality of life and disability in patients with obsessive–compulsive disorder. European Psychiatry Jun 16(4):239–245.
Bogetto F, Albert U, Maina G (2002). Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. European Neuropsychopharmacology 12, 181–186.
Bridge JA, Iyengar S, Salary CB et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. Journal of the American Medical Association 297(15), 1683–1696.
Byerly MJ, Goodman WK, Christenen R (1996). High doses of sertraline for treatment-resistant obsessive compulsive disorder. American Journal of Psychiatry 153, 1232–1233.
Bystritsky A, Ackerman DL, Rosen RM et al. (2004). Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Journal of Clinical Psychiatry 65, 565–568.
Carey PD, Vythilingum B, Seedat S et al. (2005). Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry 5, 5.
Chouinard G, Goodman W, Greist J, et al. (1990). Results of a double-blind placebo-controlled trial of a new serotonin reuptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacology Bulletin 26, 279–284.
Cleveland WL, DeLaPaz RL, Fawwaz RA, Challop RS (2009). High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period. Neural Plasticity 2009, 768398. Epub 2010 Feb 18.
Clomipramine Collaborative Study Group (1991). Clomipramine in the treatment of patients with obsessive compulsive disorder. Archives of General Psychiatry 48, 730–738.
Coric C, Sarper T, Pittenger C et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open label trial. Biological Psychiatry. Sep 1; 58(5), 424–428.
Cottraux J, Mollard E, Bouvard M, et al. (1990). A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology 5, 17–30.
Culpepper L (2002). Escitalopram: a new SSRI for the treatment of depression in primary care. Primary Care Companion Journal of Clinical Psychiatry 4, 209–214.
D’Amico G, Cedro C, Muscatello MR et al. (2003). Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 619–623.
Dannon PN, Sasson Y, Hirschmann S et al. (2000). Pindolol augmentation in treatment resistant obsessive compulsive disorder. A double-blind placebo-controlled trial. European Neuropsychopharmacology 10, 165–169.
Denys D, De Geus F, Van Megen HJ, Westenberg HG (2004). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry 65, 1040–1048.
Denys D, Fineberg N, Carey PD, Stein DJ (2007). Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biological Psychiatry 61, 412–414.
Denys D, van der Wee N, van Megen HJ, Westenberg HG (2003). A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 23, 568–575.
De Veaugh-Geiss J, Landau P, Katz R (1989). Treatment of obsessive compulsive disorder with clomipramine. Psychiatric Annals 19, 97–101.
De Veaugh-Geiss J, Moroz G, Biederman J et al. (1992). Clomipramine hydrochloride in childhood and adolescent obsessive compulsive disorder: a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry 31, 45–49.
Diniz JB, Shavitt RG, Pereira CA et al. (2010). Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. Journal of Psychopharmacology 24, 297–307. Epub 2009 Jan 22.
Drummond LM (1993). The treatment of severe, chronic, resistant obsessive-compulsive disorder. An evaluation of an in-patient programme using behavioural psychotherapy in combination with other treatments. British Journal of Psychiatry 163, 223–229.
Dunbar G, Steiner M, Bushnell WD, Gergel I, Wheadon DE (1995). Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine. European Neuropsychopharmacology 5, 372 (P-D-11).
Eddy KT, Dutra L, Bradley R, Weston D (2004). A multi-dimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clinical Psychology Review 24, 1011–1030.
Eisen JL, Mancebo MA, Pinto A et al. (2006). Impact of obsessive-compulsive disorder on quality of life. Comprehensive Psychiatry 47(4), 270–275.
Englisch S, Esslinger C, Inta D et al. (2009). Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clinical Neuropharmacology 32(4), 227–229.
Eser D, Baghai TC, Möller HJ (2010). Agomelatine: the evidence for its place in the treatment of depression. Core Evidence 4, 171–179.
Fallon BA, Liebowitz MR, Campeas R et al. (1998). Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Archives of General Psychiatry 55, 918–924.
Farre JM, Fora F, Lasheras MG (2004). Specific aspects of erectile dysfunction in psychiatry. International Journal of Impotence Research 16 (Suppl. 2), S46–S49.
Fernandez CE, Lopez-Ibor JJ (1967). Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso-Españ olas de Neurología Psíquiatría y Ciencias Afines 26, 119–147.
Feusner JD, Kerwin L, Saxena S, Bystritsky A (2009). Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacology Bulletin 42, 81–93.
Fineberg N, Pampaloni I, Pallanti S, Ipser J, Stein D (2007 a). Sustained response versus relapse: the pharmacotherapeutic goal for obsessive compulsive disorder. International Clinical Psychopharmacology 22(6), 313–322.
Fineberg NA, Gale TM (2005). Evidence-based pharmacotherapy of obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 8, 107–129.
Fineberg NA, Hawley C, Gale T (2006 b). Are placebo-controlled trials still important for obsessive compulsive disorder? Progress in Neuropsychopharmacology and Biological Psychiatry 30, 413–422.
Fineberg NA, Robbins TW, Bullmore E et al. (2010). Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 35, 591–604. Epub 2009 Nov 25.
Fineberg NA, Sivakumaran T, Roberts A, Gale T (2005). Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. International Clinical Psychopharmacology 20(4), 223–226.
Fineberg NA, Stein DJ, Prekumar P et al. (2006 a) Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. International Clinical Psychopharmacology 21(6), 337–343.
Fineberg NA, Tonnoir B, Lemming O, Stein DJ (2007 b). Escitalopram prevents relapse of obsessive-compulsive disorder. European Neuropsychopharmacology 17(6–7), 430–439.
Flament MF, Rapoport JL, Berg CJ et al. (1985). Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Archives of General Psychiatry 42, 977–983.
Foa EB, Steketee G, Kozak MJ, Dugger D (1987). Imipramine and placebo in the treatment of obsessive-compulsives: their effect on depression and obsessional symptoms. Psychopharmacology Bulletin 23, 8–11.
Fux M, Benjamin J, Belmaker RH (1999). Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. International Journal of Neuropsychopharmacology 2, 193–195.
Garcia AM, Sapyta JJ, Moore PS, et al. (2010). Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). Journal of the American Academy of Child and Adolescent Psychiatry 49, 1024–33; quiz 1086. Epub 2010 Sep 6.
Geller DA, Biederman J, Stewart SE et al. (2003 a). Which SSRI? A meta-analysis of pharmacotherapy trials in paediatric obsessive-compulsive disorder. American Journal of Psychiatry 160, 1919–1928.
Geller DA, Biederman J, Stewart SE et al. (2003 b). Impact of comorbidity on treatment response to paroxetine in paediatric obsessive compulsive disorder: is the use of exclusion criteria empirically supported in randomised controlled trials? Journal of Child and Adolescent Psychopharmacology 13 (Suppl.), S19–S29.
Geller DA, Hoog SL, Heiligenstein JH et al. (2001). Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry 40, 773–779.
Goodman WK, Kozak MJ, Liebowitz M, White KL (1996). Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. International Clinical Psychopharmacology 11, 21–29.
Goodman WK, Price LH, Delgado PL et al. (1990). Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Archives of General Psychiatry 47, 577–585.
Goodman WK, Price LH, Rasmussen SA, et al. (1989 c). Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Archives of General Psychiatry 46, 36–44.
Goodman WK, Price LH, Rasmussen SA et al. (1989 a). The Yale–Brown obsessive compulsive scale, I: development, use and reliability. Archives of General Psychiatry 46(11), 1006–1011.
Goodman WK, Price LH, Rasmussen SA et al. (1989 b). The Yale Brown Obsessive Compulsive Scale, II: validity. Archives of General Psychiatry 46(11), 1012–1016.
Grady TA, Pigott TA, L’Heureux F et al. (1993). Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. American Journal of Psychiatry 150, 819–821.
Grant P, Lougee L, Hirschtritt M, Swedo SE (2007). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology 17, 761–767.
Grant P, Song JY, Swedo SE (2010). Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology 20, 309–315.
Greenberg WM, Benedict MM, Doerfer J et al. (2009). Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. Journal of Psychiatric Research 43, 664–670. Epub 2008 Nov 30.
Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1998). Drug interactions with newer antidepressants: role of human cytochromes P450. Journal of Clinical Psychiatry. 59 (Suppl 15):19–27.
Greist J, Chouinard G, DuBoff E et al. (1995 b). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry 52, 289–295.
Greist JH, Bandelow B, Hollander E et al. (2003). Long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrums 8, 7–16.
Greist JH, Jefferson JW, Kobak KA et al. (1995 a). A one year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology 10, 57–65.
Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC (1995 c). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Archives of General Psychiatry 52, 53–60.
Greist JH, Jefferson JW, Rosenfeld R et al. (1990). Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. Journal of Clinical Psychiatry 51, 292–297.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (Revised). Bethesda, MD: US Department of Health, Education and Welfare.
Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56–62.
Harris E, Eng HY, Kowatch R, Delgado SV, Saldaña SN (2010). Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology 20, 347–353.
Hewlett WA, Vinogradov S, Agras WS (1992). Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 12, 420–430.
Heyman I, Fombonne E, Meltzer H, Goodman R (2001). Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. British Journal of Psychiatry 179, 324–329.
Hodgson RJ, Rachman S (1977). Obsessional-compulsive complaints. Behavior Research and Therapy 15, 389–395.
Hoehn-Saric R, Ninan P, Black DW et al. (2000). Multicentre double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Archives of General Psychiatry 57, 76–82.
Hohagen F, Winkelmann G, Rasche-Ruchle H et al. (1998). Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. British Journal of Psychiatry 173, 71–78.
Hollander E, Allen A, Steiner M et al. (2003 b). Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Journal of Clinical Psychiatry 64, 1113–1121.
Hollander E, Greenwald S, Neville D (1998). Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiological sample. CNS Spectrums 3, 10–18.
Hollander E, Kaplan A, Stahl SM (2003 c). A double-blind placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World Journal of Biological Psychiatry 4, 30–34.
Hollander E, Koran LM, Goodman WK et al. (2003 a). A double-blind placebo-controlled study of the efficacy and safety of controlled release fluvoxamine in patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry 64, 640–647.
Hollander E, Rossi NB, Sood E, Pallanti S (2003 d). Risperidone augmentation in treatment-resistant obsessive compulsive disorder: a double-blind, placebo controlled study. International Journal of Neuropsychopharmacology 6, 397–401.
Hollander E, Stein D, Fineberg NA, Legault M (2010). Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. Journal of Clinical Psychiatry 71(6), 784–792.
Hollander E, Wong C (1998). Psychosocial function and economic costs of obsessive compulsive disorder. CNS Spectrums 3 (5, Suppl. 1), 48–58.
Insel TR, Murphy DL, Cohen RM et al. (1983). Obsessive-compulsive disorder – a double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry 40, 605–612.
Jenike MA, Baer L, Greist JH (1990 c). Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. Journal of Clinical Psychopharmacology 10, 122–124.
Jenike MA, Baer L, Minichiello WE, Raunch SL, Buttolph ML (1997). Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. American Journal of Psychiatry 154, 1261–1264.
Jenike MA, Baer L, Summergrad P et al. (1989). Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. American Journal of Psychiatry 146, 1328–1330.
Jenike MA, Baer L, Summergrad P et al. (1990 b). Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. American Journal of Psychiatry 147, 923–928.
Jenike MA, Hyman S, Baer L et al. (1990 a). A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. American Journal Psychiatry 147, 1209–1215.
Katz RJ, DeVeaugh-Geiss J, Landau P (1990). Clomipramine in obsessive-compulsive disorder. Biological Psychiatry 28, 401–404.
Kim SW, Shin IS, Kim JM et al. (2009). The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clinical Neuropharmacology 32(4), 224–226.
Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ (1998). Behavioural versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology 136, 205–216.
Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN (2005). Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Journal of Clinical Psychiatry 66, 515–520.
Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D (2002). Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. American Journal of Psychiatry 159, 89–95.
Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association. Available at http//www.psych.org/psych_pract/treatg/pg/prac_ guide.cfm
Koran LM, Pallanti S, Querciolil L (2001). Sumatriptan, 5-HT(1D) receptors and obsessive compulsive disorder. European Neuropsychopharmacology 11, 169–172.
Koran LM, Sallee FR, Pallanti S (1997). Rapid benefit of intravenous pulse-loading of clomipramine in obsessive compulsive disorder. American Journal of Psychiatry 154, 396–401.
Koran LM, Thienemann ML, Davenport R (1996). Quality of life for patients with obsessive–compulsive disorder. American Journal of Psychiatry 153, 783–788.
Kordon A, Wahl K, Koch N et al. (2008). Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 550–554.
Kronig MH, Apter J, Asnis G et al. (1999). Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 19, 172–176.
Kruger S, Cooke RG, Hasey GM, Jorna T, Persad E (1995). Comorbidity of obsessive compulsive disorder in bipolar disorder. Journal of Affective Disorders 34, 117–120.
Kumar S, Ng B, Howie W (2003). The improvement of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine. Psychiatry and Clinical Neurosciences 57, 235–236.
Kushner MG, Kim SW, Donahue C et al. (2007). D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry 62, 835–838. Epub 2007 Jun 22.
Kwon JS, Joo YH, Nam HJ et al. (2009). Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Archives of General Psychiatry 66, 1233–1241.
Landeros-Weisenberger A, Bloch MH, Kelmendi B et al. (2010). Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. Journal of Affective Disorders 121(1–2), 175–179. Epub 2009 Jul 3.
Leckman JF, Grice DE, Barr LC et al. (1994). Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety 1, 208–215.
Lee KU, Lee YM, Nam JM et al. (2010). Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investigation 7, 55–59. Epub 2010 Feb 8.
Leibowitz MR, Turner SM, Piacentini J et al. (2002). Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 41, 1431–1438.
Leonard HL, Swedo SE, Lenane MC et al. (1991). A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry 48, 922–927.
Leonard HL, Swedo S, Rapoport JL, Coffey M, Cheslow D (1988). Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacology Bulletin 24, 93–95.
Li X, May RS, Tolbert LC et al. (2005). Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Journal of Clinical Psychiatry 66, 736–743.
Lopez-Ibor Jr J, Saiz J, Cottraux J et al. (1996). Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. European Neuropsychopharmacology 6, 111–118.
Maina G, Albert U, Ziero S, Bogetto F (2003 b). Antipsychotic augmentation for treatment-resistant obsessive compulsive disorder: what if antipsychotic is discontinued? International Clinical Psychopharmacology 18, 23–28.
Maina G, Pessina E, Albert U, Bogetto F (2008). 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. European Neuropsychopharmacology 18(5), 364–372. Epub 2008 Feb 15.
Maina G, Salvi V, Bogettoa (2003 a). Weight-gain during long-term drug treatment of obsessive compulsive disorder. European Neuropsychopharmacology 13 (Suppl.), S357.
Marazziti D, Pfanner C, Dell’Osso B et al. (2005). Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long term open-label study. Journal of Psychopharmacology 19, 392–394.
March JS (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association 16, 1969–1976.
March JS, Biederman J, Wolkow R et al. (1998). Sertraline in children and adolescents with obsessive compulsive disorder: a multicenter randomised controlled trial. Journal of the American Medical Association 28, 1752–1756.
March JS, Frances A, Kahn DA, Carpenter D (1997). The Expert Consensus Guideline series. Treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry 58 (Suppl.), 1–72.
March JS, Klee BJ, Kremer CM (2006). Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. Journal of Child and Adolescent Psychopharmacology 16(1–2), 91–102.
Marks IM, Lelliott P, Basoglu M et al. (1988). Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry 152, 522–534.
Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980). Clomipramine and exposure for obsessive-compulsive rituals. British Journal of Psychiatry 136, 1–25.
Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L (1999). Use of factor-analysed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 156, 1409–1416.
Matsunaga H, Nagata T, Hayashida K et al. (2009). A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry 70, 863–868. Epub 2009 May 5.
Mavissakalian M, Turner SM, Michelson L, Jacob R (1985). Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. American Journal of Psychiatry 142, 572–576.
McDougle CJ, Barr LC, Goodman WK et al. (1995). Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. American Journal of Psychiatry 152, 1812–1814.
McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Archives of General Psychiatry 57, 794–801.
McDougle CJ, Goodman WK, Leckman JF et al. (1993). Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. American Journal of Psychiatry 150, 647–649.
McDougle CJ, Goodman WK, Leckman JF, et al. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Archives of General Psychiatry 51, 302–308.
McDougle CJ, Goodman WK, Price LH et al. (1990). Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. American Journal of Psychiatry 147, 652–654.
McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. Journal of Clinical Psychopharmacology 11, 175–184.
McDougle CJ, Walsh KH (2001). Treatment of refractory OCD. In Fineberg NA, Marazitti D, Stein D (Eds.), Obsessive Compulsive Disorder: A Practical Guide (pp. 135–152). London: Martin Dunitz.
Micali N, Heyman I, Perez M et al. (2010). Long-term outcomes of obsessive-compulsive disorder: follow-up of 142 children and adolescents. British Journal of Psychiatry 197, 128–134.
Miguel EC, Diniz JB, Joaquim M et al. (2009). Clomipramine and quetiapine augmentation for obsessive compulsive disorder compared with sustained fluoxetine treatment. (Poster Presentation) Annual Meeting of American College of Neuropsychopharmacology 5–9 December Florida.
Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT (1987). Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. British Journal of Psychiatry 151, 107–112.
Montgomery SA (1980). Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharmacological Medicine 1, 189–192.
Montgomery SA, Fineberg N, Montgomery DB (1990). The efficacy of serotonergic drugs in OCD: power calculations compared with placebo. In Montgomery SA, Goodman WK, Goeting N (Eds.), Current Approaches in Obsessive Compulsive Disorder (pp. 54–63). Southampton, UK: Ashford Colour Press for Duphar Medical Relations.
Montgomery SA, Fineberg NA, Montgomery DB, Bullock T (1992). L-tryptophan in obsessive compulsive disorder: a placebo-controlled study. European Neuropsychopharmacology 2 (Suppl. 2), 384.
Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM (2001). Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology 16, 75–86.
Montgomery SA, McIntyre A, Osterheider M et al. (1993). A double-blind placebo-controlled study of fluoxetine in patients with DSM–IIIR obsessive compulsive disorder. European Neuropsychopharmacology 3, 143–152.
Moritz S, Ruferb M, Fricke S et al. (2005). Quality of life in obsessive–compulsive disorder before and after treatment. Comprehensive Psychiatry 46, 453– 459.
Mundo E, Bareggi SR, Pirola R, Bellodi L (1999). Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biological Psychiatry 45, 290–294.
Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E (1997 b). Long-term pharmacotherapy of obsessive-compulsive disorder; a double-blind controlled study. Journal of Clinical Psychopharmacology 17, 4–10.
Mundo E, Bianchi L, Bellodi L (1997 a). Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder; a single-blind study. Journal of Clinical Psychopharmacology 17, 267–271.
Mundo E, Guglielmo E, Bellodi L (1998). Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine; a double-blind, placebo-controlled study. International Clinical Psychopharmacology 13, 219–224.
Mundo E, Rouillon F, Figuera ML, Stigler M (2001). Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Human Psychopharmacology 16, 461–468.
Muscatello MR, Bruno A, Pandolfo G et al. (2011). Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 31(2), 174–179.
National Institute for Health and Clinical Excellence (NICE) (2006). Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder. www.NICE.org.uk
Ninan PT, Koran LM, Kiev A et al. (2006). High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. Journal of Clinical Psychiatry 67, 15–22.
Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E (2009). Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 23, 1047–1055.
Pallanti S, Hollander E, Bienstock C et al. (2002 a). Treatment-non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology 5, 181–191.
Pallanti S, Quercioli L, Bruscoli M (2004). Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Journal of Clinical Psychiatry 65, 1394–1399.
Pallanti S, Quercioli L, Koran LM (2002 b). Citalopram infusions in resistant obsessive compulsive disorder: an open trial. Journal of Clinical Psychiatry 63, 796–801.
Pallanti S, Quercioli L, Paiva RS, Koran LM (1999). Citalopram for treatment-resistant obsessive-compulsive disorder. European Psychiatry 14, 101–106.
Pampaloni I, Sivakumaran T, Hawley CJ, et al. (2009). High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. Journal of Psychopharmacology 24, 1439–1445. Epub 2009 Apr 7.
Pasquini M, Biondi M (2006). Memantine augmentation for refractory obsessive–compulsive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30(6), 1173–1175. Epub 2006 May 30.
Pasquini M, Garavini A, Biondi M (2005). Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29(1), 157–159.
Pato MT, Zohar-Kadouch R, Zohar J (1988). Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. American Journal of Psychiatry 145, 211–214.
Perse T, Greist JH, Jefferson JW, Rosenfeld R, Dar R (1987). Fluvoxamine treatment of obsessive compulsive disorder. American Journal of Psychiatry 144, 1543–1548.
Pessina E, Albert U, Bogetto F, Maina G (2009). Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. International Clinical Psychopharmacology 24(5), 265–269.
Piacentini J, Langley AK (2004). Cognitive-behavioral therapy for children who have obsessive-compulsive disorder. Journal of Clinical Psychology 60(11), 1181–1194.
Piccinelli M, Pini S, Bellantuono C, Wilkinson G (1995). Efficacy of drug treatment in obsessive compulsive disorder. British Journal of Psychiatry 166, 424–443.
Pigott TA, L’Heureux F, Dubbert B, et al. (1994). Obsessive compulsive disorder: comorbid conditions. Journal of Clinical Psychiatry 55 (Suppl.), 15–32.
Pigott TA, L’Heureux F, Hill JL et al. (1992 a). A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive compulsive disorder. Journal of Clinical Psychopharmacology 12, 11–18.
Pigott TA, L’Heureux F, Rubinstein CF, Hill JL, Murphy DL (1992 b). A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. New Research Abstracts NR 144 presented at the 145th Annual Meeting of the American Psychiatric Association, Washington, DC, USA.
Pigott TA, Pato MT, L’Heureux F et al. (1991). A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive compulsive disorder. Journal of Clinical Psychopharmacology 11, 242–248.
Pigott TA, Seay SM (1999). A review of the efficacy of selective serotonin reuptake inhibitors in obsessive compulsive disorder. Journal of Clinical Psychiatry 60, 101–106.
Pittenger C, Coric V, Banasr M, et al. (2008 a). Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 22(9):761–786.
Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V (2008 b). Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. Journal of Clinical Psychopharmacology 28, 363–367.
Rasmussen S, Hackett E, Duboff E et al. (1997). A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology 12, 309–316.
Rasmussen SA, Eisen JL (1990). Epidemiology of obsessive compulsive disorder. Journal of Clinical Psychiatry 51, 10–13.
Ravizza L, Albert U, Ceregato A (2001). Venlafaxine in OCD. Presented at the International Obsessive Compulsive Disorder Conference, Sardinia, Italy.
Ravizza L, Maina G, Bogetto F et al. (1998). Long term treatment of obsessive compulsive disorder. CNS Drugs 10, 247–255.
Reddy YC, Alur AM, Manjunath S, Kandavel T, Math SB (2010). Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 30(3), 267–272.
Reynghe de Voxrie GV (1968). Anafranil (G34586) in obsessive neurosis. Acta Neurologia Belgica 68, 787–792.
Riddle MA, Reeve EA, Yaryura-Tobias J et al. (2001). Fluvoxamine for children and adolescents with obsessive compulsive disorder; a randomised, controlled multicentre trial. Journal of the American Academy of Child and Adolescent Psychiatry 40, 222–229.
Riddle MA, Scahill L, King RA, et al. (1992). Double-blind crossover trial of fluoxetine and placebo in children and adolescents with obsessive compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 31, 1062–1069.
Robins LN, Helzer JE, Weissman MM et al. (1984). Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry 41, 949–958.
Rodriguez-Salgado B, Dolengevich-Segal H, Arrojo-Romero M et al. (2006). Perceived quality of life in obsessive-compulsive disorder: related factors. BMC Psychiatry 6, 20. doi:10.1186/1471–244X-6–20.
Romano S, Goodman WK, Tamura R et al. (2001). Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. Journal of Clinical Psychopharmacology 21, 46–52.
Rosenbaum JF, Fava M, Hoog S, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome; a randomised clinical trial. Biological Psychiatry 44, 77–87.
Rouillon F (1998). A double-blind comparison of fluvoxamine and clomipramine in OCD. European Neuropsychopharmacology 8 (Suppl.), 260–261.
Sa AR, Hounie AG, Sampaio AS, et al. (2009). Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry 50(5), 437–442. Epub 2009 Jan 15.
Savas H, Yumru M, Özen ME (2008). Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder. Clinical Drug Investigation 28(7), 439–442.
Scahill L, Riddle MA, McSwiggin-Hardin M et al. (1997). Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry 36, 844–852.
Shapira NA, Ward HE, Mandoki M et al. (2004). A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry 55, 553–555.
Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. International Clinical Psychopharmacology 11 (Suppl.), 89–95.
Simpson HB, Foa EB, Liebowitz MR et al. (2008). A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. American Journal of Psychiatry 165, 621–630.
Skapinakis P, Papatheodorou T, Mavreas V (2007). Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. European Neuropsychopharmacology 17, 79–93. Epub 2006 Aug 10.
Soltani F, Sayyah M, Feizy F et al. (2010). A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Human Psychopharmacology 25, 509–513.
Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive-compulsive disorder (OCD). Cochrane Database of Systematic Reviews 23 (1).
Stahl S (2008). Antidepressants. In Stahl's Essential Psychopharmacology – Neuroscientific Basis and Practical Applications (pp. 511–666) Cambridge: Cambridge University Press.
Stein D, Montgomery SA, Kasper S, Tanghoj P (2001). Predictors of response to pharmacotherapy with citalopram in obsessive compulsive disorder. International Clinical Psychopharmacology 16, 357–361.
Stein D, Tonnoir B, Andersen EW, Fineberg NA (2007). Escitalopram in OCD: a randomised, placebo-controlled, fixed-dose, paroxetine referenced, 24-week study. Current Medical Research and Opinion 23(4), 701–711.
Stein DJ, Carey PD, Lochner C et al. (2008). Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectrums 13 492–498.
Stein DJ, Spadaccini E, Hollander E (1995). Meta-analysis of pharmacotherapy trials of obsessive compulsive disorder. International Clinical Psychopharmacology 10, 11–18.
Stewart SE, Jenike AE, Hezel DM et al. (2010). A single-blind case-control study of memantine in severe obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 30, 34–39.
Storch EA, Lewin AB, De Nadai AS, Murphy TK (2010 b). Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. Journal of the American Academy of Child and Adolescent Psychiatry 49, 708–717. Epub 2010 Jun 2.
Storch EA, Merlo LJ, Bengtson M et al. (2008 a). D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology 22(4), 230–237.
Storch EA, Merlo LJ, Larson MJ et al. (2008 b). Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 47, 583–592.
Storch EA, Murphy TK, Goodman WK et al. (2010 a). A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry Sept 1 [Epub ahead of print].
Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C (1996). Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. Journal of Clinical Psychiatry 57, 257–264.
Tenney NH, Denys DA, Van Megen HJGM, Glas G, Westenberg HGM (2003). Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder. International Clinical Psychopharmacology 18, 29–33.
Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L (1980). Clomipramine treatment and obsessive compulsive disorder. Archives of General Psychiatry 37, 1281–1285.
Tollefson G, Rampey A, Potvin J et al. (1994). A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry 51, 559–567.
Ushijima S, Kamijima K, Asai M, et al. (1997). Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor, in the treatment of obsessive-compulsive disorder: a double blind placebo-controlled trial. Japanese Journal of Neuropsychopharmacology 19, 603–623.
Uzun O (2010). Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. Journal of Psychopharmacology 24(3), 425–427. Epub 2008 Nov 14.
Van Ameringen M, Mancini C, Patterson B, Bennet M (2006). Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open label case series. Depression and Anxiety 23, 1–5.
Vïsänen E, Ranta P, Nummikko-Pelkonen A, Tienari P (1977). Mianserin Hydrochloride (Org GB 94) in the treatment of obsessional traits. Journal of International Medical Research 5(4), 289–291.
Volavka J, Neziroglu F, Yaryura-Tobias JA (1985). Clomipramine and imipramine in obsessive compulsive disorder. Psychiatry Research 14, 85–93.
Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG (2009). Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. Journal of Clinical Psychiatry 70, 1001–1008. Epub 2009 Jun 2.
Wagner KD, March J, Landau P (1999). Safety and efficacy of sertraline in long-term paediatric OCD treatment: a multicentre study. Presented at the 39th Annual Meeting of the New Clinical Drug Evaluation Unit, FL, USA.
Watson HJ, Rees CS (2008). Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. Journal of Child Psychology and Psychiatry 49(5), 489–498.
Weissman MM, Bland RC, Canino GJ et al. (1994). The cross national epidemiology of obsessive compulsive disorder. Journal of Clinical Psychiatry 55 (Suppl.), 5–10.
Wheadon D, Bushnell W, Steiner M (1993). A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Poster presented at Annual Meeting of the American College of Neuropsycho-pharmacology, Honolulu, Hawaii, USA.
Wilens TE, Biederman J, March J et al. (1999). Absence of cardiovascular and adverse effects of sertraline in children and adolescents. Journal of American Academy of Child and Adolescent Psychiatry 38, 573–577.
Wilhelm S, Buhlmann U, Tolin DF et al. (2008). Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 165, 335–341; quiz 409. Epub 2008 Feb 1.
Wittchen HU, Jacobi F. (2005). Size and burden of mental disorders in Europe – a critical review. European Neuropsychopharmacology 15, 357–376.
Wood A, Tollefson GD, Burkitt M (1993). Pharmacotherapy of obsessive compulsive disorder: experience with fluoxetine. International Clinical Psychopharmacology 8, 301–306.
World Health Organization (1999). The “Newly Defined” Burden of Mental Problems. Fact Sheets no 217. Geneva: WHO.
Yaryura-Tobias JA, Neziroglu FA (1996). Venlafaxine in obsessive compulsive disorder. Archives of General Psychiatry 53, 653–654.
Zohar J, Judge R (1996). Paroxetine versus clomipramine in the treatment of obsessive compulsive disorder. British Journal of Psychiatry 169, 468–474.